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Type 1 diabetes (T1D) remains an untreatable autoimmune disease caused by the destruction of 
pancreatic beta cells by autoreactive T cells. Because of its complex etiology, many 
immunotherapy strategies have been investigated, but with disappointing results. Costimulation 
blockade, blocking the CD28 pathway via administration of CTLA4-Ig is a promising approach, 
but recent observations suggest its efficacy is antagonized by inflammatory factors. As antigen 
presenting cells malfunctions and aberrant accumulation of type 1 interferons are associated with 
T1D, we pose that inhibiting the signaling of inflammatory cytokines via Tofacitinib (Tofa), a 
JAK inhibitor, would enhance the efficacy of CTLA4-Ig to prevent T1D development. The 
objective of this study was to design the controlled and localized delivery of Tofa via 
implementation of biocompatible lipid nanoparticles, Nanostructured Lipid Carrier (NLC), and 
assess the immunomodulatory impact of this strategy.  
We identified a specific composition of NLC that had negligible toxicity, could be readily 
taken up intracellularly by multiple immune cells, and had a favorable Tofa encapsulation 
efficiency. Live animal imaging using fluorescently-labeled NLC confirmed that these particles 
have the unique property of accumulating in lymphoid tissues. Moreover, when administrated via 
oral gavage, they bypassed first-pass metabolism and accumulated in spleen, pancreatic and 
mesenteric lymph nodes. Ex-vivo, Tofa is rapidly delivered by Tofa-NLC to mouse antigen 
presenting cells preventing their maturation. Short-term administration of Tofa-NLC via oral 
gavage at early or later stage in NOD mouse can promote a significant reduction of T1D onset 
and delay the development of the disease. The use of CTLA4-Ig at different dosage yet did not 
give any protective effect. Current works demonstrate a promising delivery vehicle in local 
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delivery of anti-inflammatory agent, which provide therapeutic effect on T1D, and the 
mechanism(s) behind is still underway.   
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 Type 1 Diabetes and the Immunological Basis Behind It 
Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of pancreatic beta 
cells by autoreactive T cells. There are two phases of the disease. The first, insulitis, is 
demonstrated by the invasion of pancreatic islets by leukocytes. As disease progress, it becomes 
diabetes, at which the majority of beta cells (> 70%-80%) has been destroyed. At this phase, the 
islet is incapable of producing sufficient insulin to regulate blood glucose, leading to 
hyperglycemia, which serves as a diagnostic hallmark of the disease [1]. Another feature of T1D 
is the presence of beta-cell autoantigens reactive autoantibodies, such as those reactive to insulin, 
glutamic acid decarboxylase (GADA), zinc transporter 8 (ZnT8A), and insulinoma-associated 
autoantigen 2 (IA2A), and these autoantibodies can be present much earlier than symptomatic 
onset [2]. The exact cause of T1D is not clear yet, however, genetic factors have long been 
considered as the major contributor to the disease. Among numbers of genes known to affect 
disease susceptibility, the human leukocyte antigen (HLA) complex on chromosome 6 perhaps is 
the most important one, and two haplotypes in HLA class II region have been used as the 
principal susceptibility markers for type 1 diabetes. Other diverse genes are thought to contribute 
to the remaining genetic risk, yet as more studies are being conducted, it is appreciated that 
nongenetic factors, particularly environmental factors, also play a significant role in the 
development of the disease [3, 4].  
The etiology of type 1 diabetes is very complicated as both innate and adaptive immune 
system are involved in this process. The most important role the immune system played is to 
distinguish and react accordingly towards self- and non-self antigen. In healthy individuals,
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tolerance to self is maintained by the corporation of multiple regulatory mechanisms. Alterations 
in these pathways by either genetic or non-genetic drivers can lead to signals that  
break homeostasis of the immune system and diminish tolerance to self-antigens.  Centrally, self-
reactive T cells carrying autoantigen receptors are eliminated in the thymus at a very early stage 
via negative selection. However, some autoreactive T cells escape and enter the peripheral as this 
process is not perfect [5]. Peripherally, homeostasis is maintained by various regulatory 
mechanisms and damage can be prevented even with the existence of escaped self-reactive T 
cells. One of the mechanisms is the conversion of autoreactive T cells into anergic cells. To fully 
activate T cells, both antigen-specific signals delivered via T cell receptor (TCR) and 
costimulatory signals are required. Fully activated T cells can then divide and differentiate into 
effectors and regulators, participating into immune responses. Providing TCR engagement alone 
will lead T cell to a state called anergy, in which they are functionally inactive (i.e. reduced 
effector functions, proliferation, and cytokine production) but can remain alive for an extended 
period [6, 7]. Another mechanism, activation-induced cell death (AICD), utilizes Fas and Fas 
Ligands (FasL) interaction. Activation of Fas expressed on beta-cells by FasL expressed 
activated T cells can induce apoptosis and lead to deletion of peripheral activated T cells. It has 
been demonstrated that in both mice and human, defects in Fas or FasL can initiate the 
development of multiple autoimmune diseases [7-9]. The third mechanism prevents autoimmune 
reactions by suppressing self-reactive lymphocytes via regulatory T cells (Treg). There are 
various subsets of Tregs (i.e. type 1 Tregs and T helper 3 Tregs), and they are mainly 
characterized by the expression of forkhead box transcription factor P3 (Foxp3). It has been 
clearly shown that loss-of-functions mutations of Foxp3 can lead to early onset of T1D in human 
and deficiency of Treg cells in mouse model can accelerate T1D, both indicating that Treg plays 
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a critical role in maintaining self-tolerance and regulating the development of the disease. It is 
now known that the suppressive function of Treg is applied either directly on effector T cells by 
producing immunosuppressive cytokines such as IL-10 and TGF-, or indirectly on DCs by 
inhibiting their maturation and function [7, 8, 10]. However, these regulatory mechanisms can be 
disrupted, leading to off balance of the immune system and potentially initiating responses 
against self-tissue.  
Activation of innate immune cells is often a pre-requirement in this loss-of-tolerance 
process. Some populations of antigen presenting cells (i.e. dendritic cells (DCs)) as well as 
innate signaling pathways (i.e. type 1 interferon (IFN)) have been closely related to triggering 
autoimmune responses [5]. Conventional dendritic cells (cDCs) can facilitate the initiation of 
disease by presenting self-antigens released from the body, while plasmacytoid DCs (pDCs) do it 
by secreting large amount of interleukin 12 (IL-12) and type 1 IFNs. The correlation of type 1 
IFN with the initiation of T1D has been demonstrated in studies, in which the incidence increases 
as the production of type 1 IFN by pDCs in pancreatic lymph node (pLNs) increases  [8, 11]. 
Macrophages also play a pathogenic role in both onset and destruction phases of T1D. Early 
experiments showed blocking the influx of macrophages into pancreas can inhibit the 
development of diabetes, and recently this is thought to be related to the production of IL-12, IL-
1, tumor necrosis factor (TNF), and reactive oxygen species (ROS) [12, 13].  In addition, 
certain viral infections (i.e. enteroviruses) have been considered to promote on environment that 
activated the innate immune system and initiates T1D. Viruses can influence beta-cells by direct 
or indirect damage to the cells, thus enhancing the release of beta-cell antigens. Indirectly, the 
infection in pancreas caused by viruses can trigger the recruitment of innate immune cells and 
activate autoimmunity, which is recently thought to be related with type 1 IFN production [5, 8, 
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14]. Other potential environmental influences thought to be related to the disease including 
exposition to microbiome, climate change, and nutrition [15, 16]. 
With various immune cells and complex pathway involved and multiple regulatory 
mechanisms built, a healthy immune system is able to prevent attacking of self-tissues and 
provide self-tolerance. However, any breaking points within the system can potentially lead to 
the initiation of the disease. For type 1 diabetes to develop, multiple events are needed: 
diabetogenic T cells need to be activated, the response need to be strongly proinflammatory, and 
last but not least, the regulatory control against autoreactive responses need to be ineffective 
[10]. Antigen presenting cells (APCs) such as DCs are important for activation of anti-islet 
response. They first take up and process beta-cell derived antigens (released due to beta-cell 
death) within islet and then migrate to the draining pancreatic lymph nodes (PLNs), where they 
present antigens to beta-cell reactive T cells and activate them [1]. The full activation of T cells 
requires stimulation of TCR by major histocompatibility complex (MHC), which is facilitated by 
appropriate costimulatory signals as well as macrophages (through the secretion of IL-12) [8, 
17]. Activated T cells can then migrate back into islets, destroying beta-cells by releasing pro-
inflammatory agents such as IFN-γ, perforin and granzymes, resulting in the initialization of 
insulitis [1]. In addition of cytotoxic helper T cells, B cells, dendritic cells, and macrophages can 
also infiltrate into pancreatic islet and causing beta cell damage by producing, for instance, tumor 
necrosis factor (TNF), IL-1, and nitric oxide [8]. Damages on beta-cells can be controlled by 
aforementioned regulatory mechanisms, yet if these mechanisms failed, the destructions will 
continue to expand and eventually progress to diabetes.  
 Current Treatments, Clinical Trials, and Research 
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Worldwide, the incidence of type 1 diabetes has been increasing. Approximately 1.25 million 
American has type 1 diabetes, and about 40,000 people in the U.S. will be newly diagnosed each 
year. Much effort has been put into the clinical care of T1D to help improve the quality of a 
patient’s life and clinical outcomes. Although numerous therapeutic options have been 
investigated and developed, type 1 diabetes, unfortunately, still remains a disease with no cure. 
Current existing treatments mainly focus on managing blood glucose level through 
administration of insulin. Patients depend on lifelong continuous insulin administration, and 
receive multiple daily injections, including rapid acting insulin with meals and continuous 
infusion of basal insulin [3]. Despite the utilization of various insulin delivery technologies (i.e. 
insulin pumps and continuous glucose monitors), many patients suffers devastating 
consequences associated with poor glycemic control including cardiovascular and perivascular 
disease, nephropathy, retinopathy, and neuropathy [18].  
Many therapeutic approaches using immunological interventions have been investigated 
in order to prevent or delay the development of T1D. Many clinical trials have been conducted to 
preserve beta-cell functions by inducing immune tolerance through induction of antigen-specific 
tolerance or immune suppression. The most commonly used diabetes-specific antigens are 
insulin and L-glutamic acid decarboxylase (GAD), and these antigen-based immunotherapies are 
beneficial in a way that they are specific for T1D autoantigens. The immune suppression is 
usually performed by targeting T cells with anti-CD3 antibodies (i.e. otelixizumab and 
teplizumab), targeting B cells with anti-CD20 antibodies (i.e. rituximab), and preventing immune 
activation with the presence of a costimulation blocking agent (i.e. abatacept). Although some 
trials showed a transient effect, unfortunately, to date no trail have known to succeed the 
preservation of beta-cell function. There are many other attempts at immune intervention in T1D 
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as well, yet with mixed results [2, 19]. These unpromising outcomes from previous trails may be 
related to the choice of antigen or dosing regimen, yet they may also imply that single target 
immunotherapy trials alone are not sufficient in comprehensively controlling beta-cell 
destruction. Thus, a consensus is emerging that more effective therapy would be a combinatory 
therapeutic approach using agents with complementary effects. 
In the past, trials targeting more than one molecule at the same time have been tested as 
multiple targetable pathways are involved in the development of T1D.  For example, one of the 
earliest trials combined mycophenolate mofetil (MMF) with daclizumab (DZB), an 
immunosuppressant used for organ transplant able to control proliferation of T- and B-cells and 
an antagonist of  subunit (CD25) of IL-2 receptor on activated T- and B-cells, respectively. A 
phase one trail focused on combining rapamycin with IL-2, aiming to improve Treg function in 
recent-onset T1D.  Rapamycin, also used in organ transplant, has inhibitory function on pro-
inflammatory Th1 and Th17 T cells, and IL-2 works on different cell types expressing IL-2 
receptors, stimulating and expanding regulatory T cell populations.  More recently, GAD65 
loaded aluminum hydroxide vaccine (GAD-alum) combined with vitamin D via intralymphatic 
and oral administration respectively was tested. Although these trials showed positive results in 
either delaying disease onset in animal model or increasing Treg cell population in human trails, 
adverse effects (i.e. neutropenia and leukopenia) were frequently reported, which could be 
possibly due to that combining molecules at same time would also amplifying adverse effects 
[20, 21]. This indicates that simply applying an immunosuppressive agent and an 
immunoregulatory agent is not an ideal approach for developing combination immunotherapy. 
Learning from all previous research trails as well as appreciating the complex immunological 
basis of self-tolerance and environmental influences on T1D, we argue that an ideal combined 
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immunotherapeutic approach should contain a source of diabetes-related antigen that can confer 
specificity to the treatment, combined with an immunomodulatory agent regulating adaptive 
immune cells and perhaps favoring the accumulation of Tregs and an anti-inflammatory agent 
targeting innate immune cells by controlling the release and effect of pro-inflammatory 
cytokines.  
 
 Costimulation Blockade (CoB) 
Learning from previous immunological approaches, we attempt to restore regulation of 
diabetogenic T cells employing a modification of therapeutic strategy called “Costimulation 
Blockade (CoB)”, which controls T cell activation and promotes induction of T cell tolerance by 
blocking the CD28 pathway. Despite the existence of many other costimulatory pathways, CD28 
pathways is one the most potent and well-characterized. The CD28 pathway, which involves 
CD28 (T-cell-specific surface glycoprotein CD28), CD80 (T lymphocyte activation antigen 
CD80), and CD86 (T lymphocyte activation antigen CD86), has been well studied, and it playes 
a pivotal stimulatory role in T cell activation and proliferation. CD28 is a co-stimulator 
constitutively expressed on the surface of T cells, which binds to CD80 and CD86 expressed on 
APC surface, and the interaction of CD28 with CD80/CD86 contributes to T cell proliferation 
via several mechanisms, including increasing IL-2 transcription and mRNA stability, increasing 
anti-apoptotic protein Bcl-XL, and decreasing T cell activation threshold [22, 23]. Therapeutic 
blockade of this pathway in autoimmunity and transplantation models was studied decades ago, 
which mainly utilized an immunoglobulin (Ig) fusion protein CTLA4-Ig (“abatacept”) to bind 
CD80 and CD86 and thereby blocking the activation of CD28 signaling [22]. Clinical trials using 
abatacept in autoimmune diseases has long been investigated, and abatacept has been approved 
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for treatment of rheumatoid arthritis (RA) by the FDA [24]. In type 1 diabetes, abatacept slows 
the loss of beta-cell function, however, this only applies to the period immediately after 
diagnosis. Long-term, the inhibition of naïve T cell activation and expansion is limited, and it has 
no significant differences with placebo [25]. In the context of transplantation, costimulation 
blockade can help induce immune tolerance of the graft. Research over the past decades has 
shown that CTLA4-Ig is a potent modulator of transplant rejection and it can induce prolonged 
graft survival. CTLA4-Ig administrated at the time of graft implantation can induce long-term 
cardiac allografts in rats, and it can also increase allograft survival of liver, kidney, and lung 
transplants in rodent animals [26, 27]. In addition to small animals, blockade of CD28 pathway is 
also capable in inducing prolonged allograft survival in large animals. In CTLA4-Ig treated non-
human primates, allogeneic kidney or islet transplants are retained much longer comparing to 
untreated controls, yet long-term graft survival is not achieved [28].  
To date, many findings confirmed the role of CD28 pathway in regulating immune response 
and blockade of the pathway with CTLA4-Ig is capable of inducing protective effect in both 
autoimmune and transplant models. In all these models, it is thought that the protective effect of 
CoB is obtained by promoting an anergic state in T cells and stimulating the accumulation of 
Treg. However, the effects of CoB by blocking CD28 pathway with CTLA4-Ig alone is still very 
limited, and itself is not able to prevent all T cell proliferation or transplant rejection, and is not 
sufficient in inducing tolerance. Many factors have been considered to contribute to the 
limitation of CTLA4-Ig, including for instance, memory T cell resistance, deleterious effect on 
regulatory T cells, and non-redundant co-stimulation [29]. In term of transplantation, based on 
growing body of evidence, the limitation of CTLA4-Ig in inducing long-term graft survival is 
measurably due to inflammatory responses, which could be caused by infections either pre- or 
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post-transplantation [30]. These infections are generally caused by pathogenic bacteria, fungi, or 
viruses and are observed to be associated with acute or chronic transplant rejection. It is 
suggested that the inflammatory effect is due to the production of pro-inflammatory cytokines by 
directly response to pathogen and/or to autoantigens (cryptic antigens) exposed following cell 
damage [31]. The important role of inflammatory cytokines in promoting T cell activation has 
been introduced previously. Under inflammatory conditions, infections can enhance the 
maturation of APCs, which lead to increased release of inflammatory cytokines, ultimately 
promoting the activation of T cells in a CD28-independent manner [30]. In type 1 diabetes, 
inflammatory responses can be induced via innate signal and/or viral infection, and this might 
contribute to some understanding of the limited success in long-term preservation of beta-cell 
function in recent trials. Therefore, we pose to introduce an anti-inflammatory agent into the 
previously developed “Costimulation Blockade” strategies to inhibit the signaling of 
inflammatory cytokines and consolidate the modulatory effect of CTLA4-Ig. This will achieve 
what we define “Enhanced Costimulation Blockade” (ECoB), which favors the induction of 
insulin-specific T cell tolerance and promotion of Treg activity.  
 
 Enhanced Costimulation Blokade (ECoB).  
Our previous studies using transplant models have confirmed that the protective effect CTLA4-
Ig has on T cells can be neutralized by the inflammatory cytokines released from matured APCs. 
We were also able to identify a small molecule, Tofacitinib (Tofa), as an anti-inflammatory 
agent, to provide pharmacological inhibition on the signaling pathway and production of a class 
of inflammatory cytokines [32].  
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The role inflammatory cytokines (i.e. Type 1 IFN) played on immunopathogenesis of 
autoimmune disease, particularly in T1D, has been described previously, and it’s been 
recognized that many cytokines involved in inflammation and autoimmune disease use Jak 
pathway for intracellular signal transduction [33]. With the existence of two major classes of 
cytokine receptors, type I and type II, multiple families of cytokines are able to be recognized by 
this pathway, including interleukins colony stimulating factors (by type I) and interferons and IL-
10 related cytokines (by type II) [32]. Upon interaction with their cognate cytokines, cytokine 
receptors are activated and bind to their paired members of Janus Kinases (Jaks), which includes 
Jak 1, Jak2, Jak3, and Tyk2. Ligand-induced heterodimerization results in recruiting of multiple 
signaling molecules (i.e. signal transducer and activator of transcription (STAT)), thus lead to a 
series downstream signaling of various cytokines that are critical to inflammatory responses [5, 
33, 34]. Tofacitinib (Tofa) is a Jak inhibitor that inhibits mainly Jak1 and Jak3. It also has some 
activity on Jak2, yet negligible on Tyk2 [35]. Mechanistically, Tofa is able to block common c 
cytokines signaling (i.e. IL-2, IL-4, IL-7…) through Jak3, and gp130 family (i.e. IL-6 and IL-
11), IFN family (i.e. IFN- and IFN-), and IL-10 family (i.e. IL-10) cytokines through Jak1 
[32]. Due to the broad range of cytokines Tofa can target, it has been tested as a potential 
treatment in both transplantation and autoimmune disease. In transplantation, murine cardiac 
model and nonhuman primate renal model have demonstrated prolonged graft survival when 
treated with Tofacitinib [36], and clinical trials are currently ongoing to identify the proper 
dosage of Tofa usage in kidney transplantation [37]. More applications of Tofacitinib are in 
autoimmune diseases, and it has shown promising results in multiple clinical trials. One of the 
most successful one is in rheumatoid arthritis (RA), in which, when applied as monotherapy in a 
phase III trial, symptoms of active RA was reduced and physical function enhanced [38]. 
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Combined with methotrexate in a phase IIb trail, Tofa treatment also showed efficacious results 
in RA reported by another study [39]. With all these results showing efficacy in treating RA, 
Tofacitinib has been approved in 2012 by the US FDA to treat moderate-to-severe RA in adult 
patients with inadequate response to methotrexate [40].  
Our group has previously demonstrated in a heterotopic heart transplant mouse model 
that the “Enhance Costimulation Blockade” (ECoB) strategy utilizing CTLA4-Ig combined with 
short-course Tofa administration is able to prevent alloreactive T cell activation and promote 
graft survival, which is mechanistically caused by accumulation of Treg cells in target tissues 
and reduced generation of effector T cells (i.e. IFN- producing Th1). With the demonstrated 
promising results of the ECoB strategy in transplantation, we plan to further optimize it and 
apply it for proper immune modulation in Type 1 diabetes.  
Tofacitinib is a synthetic drug feasible for oral administration [40], which comparing to 
current applied administration route is more attractive and ideal as it is a non-invasive, pain free 
delivery method favoring patient compliance. However, the therapeutic use of this drug is mainly 
affected by two limitations, side effects and short half-life. Tofacitinib has been reported to have 
deleterious side effects associated with prolonged systemic use. Serious infection is one of them 
and it can be caused by virus, bacteria, and fungi. Multiple clinical trials of Tofa have reported 
increased incidence of opportunistic infections including tuberculosis (TB) and non-disseminated 
herpes zoster [32].  Another concerning side effect is the development of post-transplant 
lymphoproliferative disorder (PTLD). PTLD covers a broad range of disorders from hyperplasia 
to lymphoma, and its incidence has been reported in a phase IIb trail, in which some patients 
developed it in a broad range of time point after using Tofa [41, 42]. Other side effects that have 
been reported include: hypercholesterolemia [43], minor increase in creatinine [32], and 
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increased risk of cancer [44]. Tofa’s short half-life is another limitation for its in vivo use. 
Although this might be a potential advantage in controlling infection, maintaining Tofa at a 
consistent therapeutic concentration within the body becomes very challenging. The 
pharmacokinetics of Tofa has been reported, and the mean half-life for 5, 15, and 30mg b.i.d 
doses are 5.2, 5.2, and 3.7 hours, respectively. The peak plasma concentration can be reached 
within half to an hour following administration, and the elimination half-life is about 3 hours 
[40]. In order to overcome the aforementioned limitations in Tofa administration, its half-life 
need to be prolonged and its application need to be modified in a short-term and localized 
manner. Thus, we propose to introduce nanoparticle delivery system into our ECoB strategy, 
aiming to achieve short course use as well as controlled and localized delivery of Tofacitinib.  
 
 Nanoparticle Delivery System 
Nanoparticles are solid or spherical structures typically size in the range of 100-250 nm, and 
delivery systems using nanoparticles have been studied over the past decades. The 
manufacturing of nanoparticles using different materials has been characterized, and their 
utilization in therapeutic development have been demonstrated. Many researches have been 
focusing on polymer-derived nanoparticles (i.e. Poly(lactic-co-glycolic acid) (PLGA)), and they 
have been commonly used in biomedical applications due to multiple attractive properties 
including biodegradability and biocompatibility, well described formulation and adaptability to 
various types of drugs, possibility to modify surface properties, possibility of site-specific 
targeting, etc. [45] However, polymeric nanoparticles’ application in therapeutic and 
pharmaceutic approaches remains challenging, as it has limited drug loading efficacy as well as a 
drug expulsion potential. Although the mean encapsulation efficiency of polymer nanoparticles 
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is around 60 to 70% depending on drug types, the drug loading efficiency is generally very poor 
(around 1%) [46], which is a major disadvantage in designing effective delivery systems. 
Another important pitfall is the high burst release that is generally seen in polymer nanoparticle 
designs, and this is probably due to the “nano” nature of particles as size is essential and larger 
particles tend to have smaller initial burst release [46]. Emerging studies on lipid-based particles 
have shown various unique properties of this class, which makes them an alternative to polymer 
nanoparticles in therapeutic applications.   
The class of lipid-based nanoparticles can be divided into multiple subsets, including 
solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). They are nowadays 
considered better drug delivery platforms, as they retain the attractive properties of polymer 
nanoparticle while minimizing the associated problems [47].  SLN is the first generation of lipid 
nanoparticles (LNp), and they are made from physiological solid lipids (i.e. fatty acid and 
triglycerides) and stabilized by surfactant(s) (i.e. poloxamer and polysorbate), which are 
generally regarded as safe by the FDA [47, 48]. SLN is featured by physical stability, 
biocompatibility, tolerability, targeted delivery, and controlled release of broad range of 
ingredients. However, despite exceeding polymer nanoparticles, its drug loading efficiency 
(approximately 25-50%) is still insufficient and drug expulsion possibility remains high, which is 
very likely due the use of highly complexed lipid lattice structures and the crystal imperfections 
formed [49]. In order to improve the feasible properties and overcome the difficulties in SLN, 
NLC was introduced and developed in the late 1990s. There are so far 3 types of NLCs, the 
“imperfect type NLC”, the “multiple type NLC”, and “amorphous type NLC”. The first two 
types are able to enhance drug loading efficiency and prevent drug expulsion using spatially 
different lipids (at different ratios), by which space between glycerides’ fatty acid chains and 
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crystal imperfections is increased, allowing more guest molecules accommodation. The highest 
drug load by now is achieved by mixing solid lipids with liquid lipids (oils) at a certain ratio to 
form a best controlled nanostructure [50]. Since crystallization is the major cause of current drug 
expulsion in SLN, NLC is able to avoid crystallization upon cooling by mixing special lipids 
[51]. In addition of reducing drug loading and expulsion problems, lipid-based nanoparticles 
have been demonstrated by many studies to bypass biological barriers and accumulate in 
lymphatic system [48, 52, 53], which is a unique property not shared by other nanoparticles that 
makes them appealing for lymphatic delivery.  
Lymphatic system plays an essential role in transporting extracellular fluid, regulating 
lipid metabolism, and controlling immune responses. In term of transportation, it not only 
provides channels for lymphocytes and APCs to travel from tissues to draining lymph nodes, but 
also helps transport dietary lipids from the intestine to the general circulation and helps clear 
fluid and multiple molecules (i.e. proteins and bacteria) into endogenous carriers from peripheral 
tissues into systemic circulation [54]. Size of a molecule is important to determine through which 
pathway they will enter the system. For majority of small molecules, since blood flow rate is 
much higher (> 100-500-fold) comparing to lymph flow, they tend to drain into blood capillaries 
from interstitial space rather than lymphatics. Yet for macromolecules (i.e. proteins), entry into 
blood is usually restricted by their size and their access is promoted to the lymphatics. It has been 
reported that the pathway for lymphatic uptake of therapeutic macromolecules is similar to that 
of endogenous macromolecules, in which molecules size 10 nm or lower will enter blood 
capillaries primarily and those larger than 100 nm will also have restricted access to lymphatic 
due to reduced diffusion and convection from injection site [55]. Only particles size between 10-
100 nm can diffuse through interstitium and access lymphatic vessels [55, 56]. Besides size, 
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factors that influences interstitial fluid pressure and flow can also alter lymphatic transport [54]. 
In addition to passively entering lymphatics from interstitial tissue, therapeutics can also be taken 
up by APCs through phagocytosis in the extracellular matrix and then traffic to draining lymph 
node via afferent lymphatic vessels, in which size and surface charge also play a critical role. 
Typically, APCs are more likely to take up larger (500-2000 nm) and positively charged 
molecules, whereas smaller neutral molecules (< 50nm) will drain directly to lymphatics [57, 
58].  
To reach the ultimate goal of delivering drug via oral administration, drug delivery 
systems must first pass the intestinal barrier and access to the interstitial space underneath, which 
is a common limitation for oral delivery since the stability within the harsh environment of 
gastrointestinal tract and permeability across intestine are generally very low [54]. For 
nanoparticles to be taken up intestinally, various characteristics need to be taken into 
consideration such as size, shape, surface charge, and stability (physical and chemical) [59]. 
Thus, being able to cross biological barriers is a huge advantage of lipid nanoparticles, and it 
further grants the possibility of accessing to lymphatic system. Lymphatic uptake of orally 
administrated macromolecules such as therapeutic proteins and nanosized delivery systems has 
been studied for decades, and it is suggested that upon absorption by intestine, a large proportion 
are expected to entering intestinal lymphatics [59]. 
In addition to transportation, lymph nodes also serve as site for immune surveillance and 
initiate immune responses, which makes the lymphatic uptake of therapeutic agents an important 
strategy for treating immune-related disease [55]. After entering lymph node, particles may pass 
through and then leave via the efferent lymph, or be taken up by different cells within lymph 
nodes and be retained there. Larger particles are more likely to be taken up by subcapsular 
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characterizations, in term of particle size, polydispersity, and thermal behavior, that are suitable 
for encapsulating Tofacitinib (Tofa-NLC) with high encapsulation efficacy (79%). To this end, 
we propose that controlled and localized delivery of Tofacitinib via implementation of 
biocompatible lipid nanoparticles, Nanostructured Lipid Carrier (NLC), will maximize Tofa’s 
synergy with CTLA4-Ig (actuating ECoB) and promote an effective regulation in the onset and 
development of type 1 diabetes. 
   
        
                        
MATERIALS and METHODS 
 Nanoparticles 
All nanoparticles including NLC loaded with far red dye Dilc (Dilc-NLC), NLC loaded with 
Tofacitinib (Tofa-NLC), and NLC without any cargo (Ctrl. NLC) were manufactured by our 
collaborators at Johns Hopkins Applied Physics Laboratory. Dilc-NLC was provided at a 
concentration of 150 mg/ml, in which Dilc was contained at 0.375 mg/ml. Tofa-NLC and Ctrl. 
NLC were prepared at 150 mg/ml as well, but Tofa-NLC also contained 2 mg/ml Tofa.  
 
 Animal 
NOD/ShiLtJ (NOD) mice were purchased from The Jackson Laboratory. All mice were housed 
and bred under barrier conditions in Johns Hopkins University animal facility at Miller Research 
Building. All animal studies have been proved by Johns Hopkins Animal Care and Use Program.  
 
 Cell and Tissue Preparation 
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Cell Culture. Dendritic cells were cultured from NOD bone marrow in complete medium with 
growth factors GM-CSF (PeproTech, car#315-03-100UG) and IL-4 (PeproTech, cat#214-14-
250UG) at 300U/ ml and 20U/ ml, respectively. Complete medium was made from 500 ml 
RPMI-1640 Medium (Quality Biological, cat#112-301-101), 50 ml Fetal Bovine Serum (Atlanta, 
cat#S11095), 10.2 ml Penicillin Streptomycin Solution 50x (Corning, cat#30-001-CI), 5.1 ml 
Hepes Buffer Solution 100x (Gibco, cat#15630-080), 5.1 ml MEM Non-Essential Amino Acid 
Solution 100x (Gibco, cat#11140-050), 5.1ml Sodium Pyruvate Solution (100mM) (Sigma, 
cat#S8636-100ML), 5.1ml Glutamax Solution 100x (Gibco, cat#35050-061), and 500µl beta-
mercaptoethanol 100x (Gibco, cat#21986-023). For toxicity, NLC uptake, and maturation tests, 
bone morrow cells were cultured in 6-well plate (0.25x106 cells in 2 ml complete medium per 
plate). For confocal imaging, cells were cultured in p-100 culture dish with 2x106 cells in 10 ml 
complete medium per plate.  
 
Tissue Digestion. In NLC ex vivo and cellular uptake as well as APC maturation test, spleen and 
lymph nodes were extracted and digested using digestion buffer, which is made from 
Collagenase IV at 1mg/ml (Worthington, cat#LS004186) and DNase I at 0.1 mg/ml (Roche, 
cat#10104159001) in RPMI-1640 medium. Digestion buffer was applied 5 ml per spleen and 1 
ml per lymph node type, and tissues were digested in incubator for 30 minutes with a magnetic 
stir bar applied.  
 
 Flow Cytometry 
Cells were collected after preparation and blocked with anti-CD16/32 (2.4G2, BD Biosciecne, 
cat#553142), followed by staining of appropriate antibodies against surface proteins in MACs 
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buffer for 30 minutes at 4oC. In some experiments, viability dye was stained at a concentration of 
0.4 µl/ml in PBS for 20 minutes at 4oC, and intracellular protein was stained for 30 minutes at 
4oC after fixing and permeabilizing cells with Fix & Perm Buffer (Fixation/Perm Diluent 
(eBioscience, cat#00-5223-56) and Fixation/ Perm Concentrate (eBioscience, cat#00-5123-43) in 
3:1 ratio). In tetramer related experiments, dye and antibodies used included: viability 
(eBioscience, cat#65-0863-14), anti-CD11c (N418, eBioscience, cat#48-0114-82), anti-CD11b 
(M1/70, eBioscience, cat#48-0112-82), anti-B220 (RA3-6B2, eBioscience, cat#48-0452-82), 
anti-TER-119 (TER-119, eBioscience, cat#48-5921-82), anti-CD3 (145-2C11, BioLegend, 
cat#553061), anti-CD4 (GK1.5, BioLegend, cat#100423), and anti-FoxP3 (FJK-16s, 
eBioscience, cat#45-5773-82). In all other experiments, cells were stained with following dye 
and Abs: viability (eBioscience, cat#65-0865-14), anti-CD11c (N418, eBioscience, cat#11-0114-
85), anti-CD11b (M1/70, eBioscience, cat#45-0112-80), anti-CD3 (17A2, eBioscience, cat#48-
0032-82), anti-B220 (RA3-6B2, BioLegend, cat#103208), anti-CD40 (1C10, eBioscience, 
cat#12-0401-83), anti-CD80 (16-10A1, BioLegend, cat#104714), anti-CD86 (GL1, eBioscience, 
cat#48-0862-82). After staining, cells were measured on a BD LSRII flow cytomerter (BD 
Bioscience) and analyzed using FlowJo software (version 10.5.3, TreeStar) 
 
 Imaging 
Confocal Imaging. BMDCs were collected and incubated (at 1x106 cells/ml) with Dilc-NLC 
solution (at 1 µg/ml) in complete medium at 37oC for different duration. Incubation was stopped 
by adding ice cold PBS and cells were then stained for CD11c-BV421 (N418, BD Bioscience, 
cat#565451) in MACs buffer for 20 minutes at 4oC. Cells were resuspended into MACs buffer at 
2.5x106 cells/ml after staining, and 50 µl of the cell solution was added to the center of 35 mm 
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glass bottom dish (Cellvis, cat#D35-20-1.5-N). Confocal fluorescent images were obtained by 
ACCM Leica SP8 Confocal Microscope with the utilization of lasers at 405 nm and 638 nm and 
detectors HyD1 and HyD3. Images were analyzed using the software Leica Application Suite X 
(LAS X, version 3.5.2). 
 
IVIS. Fluorescent signal in NLC biodistribution and kinetics studies was detected by IVIS 
Spectrum imaging system (Perkin Elmer), during which the excitation and emission wavelengths 
were set to 675 and 760nm respectively, and the exposure time set to auto. Average radiant 
efficiency (p/s/cm2/sr)/(µW/cm2) in the regions of interest (ROI) was measured as an index to 
assess the intensity of fluorescent signal.  
 
 Tetramer Staining 
PE- and APC-labeled InsB10-23r3:I-Ag7 tetramers were purchased from the National Institutes of 
Health tetramer core. Cells were collected after preparation and tetramer-binding cells were 
enriched by staining both tetramers at 6µg/ml in Fc block (anti-cd16/32 (1:100) + Macs buffer + 
2% mouse serum + 2% rate serum) at room temperature for exactly 1 hour in dark. Anti-PE 
(Miltenyi Biotec, cat#130-048-801) and anti-APC (Miltenyi Biotec, cat#130-090-855) 
MicroBeads were then applied at the volume of the cell pellet for 30 minutes at 4oC, followed by 
positive selection using autoMacs separator (Miltenyi Biotec). Tetramer-binding cells were 
collected from the positive column and then underwent flow staining for different markers.  
 
 Statistical Analysis 
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Survival benefit was determined by Log-rank test using Prism software package (version 7.0a, 
GraphPad Software, 2016). P values less than 0.05 was set to be the threshold for any 




 Nanostructured Lipid Carrier (NLC) characterization: Uptake, Biodistribution, and 
Kinetics 
NLC Toxicity. The toxicity of our formulation of NLC was first tested before any further 
experiments to assure the particle itself will not harm cells and have a proper working range. The 
NLC toxicity was assessed by evaluating the induction of cell death following co-culture with 
NOD bone marrow derived dendritic cells (BMDCs). Titration of NLCs were co-cultured with 
BMDCs overnight. Cells were then stained for viability dye and dendritic cell surface marker 
(CD11c) and analyzed via flow cytometry to determine the percentage of dead cells (Figure 2). 
Overall, no significant toxicity was identified at the concentrations tested. NLC particles has low 
toxicity to DCs until reaching a concentration of 500 µg/ml, where little toxicity starts to be 
observed, and it guaranteed a relatively broad range of dosage to be applied in the future. 
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particle can be taken up by cells. The much stronger uptake was displayed only at initial time 
frame, yet no further uptake was observed (according to overlapping peaks). Although with 
limited time points acquired, this indicated that at 10 minutes or even earlier after incubating 
with DCs at this concentration, the uptake has already reached to a saturation stage. Based on 
this set of data, 1 µg/ml is the best concentration to apply Dilc-NLC among all concentrations 
tested, for it’s able to show a continuous uptake of the particles over a broad range of incubation 
time points. Moreover, it reflects that the particles are taken up with an initial quick uptake 
followed by a continuous gradual one. 
With these results shown, our NLC particles are readily taken up by dendritic cells. 
However, this assessment via flow cytometry does not necessarily reflect whether the NLC 
particles are attached on the surface of DCs or taken intracellularly. To further explore NLC 
uptake, confocal microscopy was used to directly and visually study the uptake profile of NLC.  
              
Bone marrow derived dendritic cells were co-cultured with Dilc-NLC at 1 µg/ml (as 






 10 min 
0 min 
Figure 3.NLC can be readily taken up in vitro. Representative cellular uptake of NLC loaded with far-
red dye Dilc (Dilc-NLC) by BMDCs. Dilc-NLC at different concentration (0.1, 1, or 30 µg/ml) were co-
cultured with BMDCs (5x105
 
cells) for different amount of time (0,10, 20, 30, 45, 60, or 120 minutes) in 
the incubator. Following incubation, cells were stained for dendritic cell marker CD11c. The uptake of 
Dilc-NLC particle is determined by assessing the fluorescent intensity of the far-red dye via flow 
cytometry, which is analyzed within CD11c+ single cell population. (Only 3 time points were showed in 
the 30 µg/ml group due to restrictions experienced at acquisition).  
0.1µg/ml 1µg/ml 30µg/ml 
Dilc-NLC 
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more precise analyzation. From the confocal images of different exposure time (Figure 4), only 
the contour of dendritic cells is exhibited when no NLC particles were added in, yet NLCs can be 
clearly seen located inside the plasma area of dendritic cells at all time points when applied.  The 
amount of NLC intake on a per cell base, however, do not seem to differ between initial and later 
timepoints, and particles can already be observed intracellularly as early as 10 minutes, which all 
correlate to the flow data represented previously. Using confocal imaging allow us to identify 
that our formulation of NLC can be readily taken up intracellularly, and it also allows us to study 
on the uptake process of NLC particles by dendritic cells (experiment ongoing). 
 
Ex Vivo NLC Uptake. Antigen presenting cell populations are critical for antigen presentation 
during immune responses and in addition to DCs, they include macrophages and B cells. 
Considering the much different environment in vivo, which lead to the development of 
CD11c-BV421; NLC-Dilc 
0 min (No particles) 10 mins 
30 mins 60 mins 
Figure 4.NLC are readily 
internalized. Representative 
cellular uptake of Dilc-NLC by 
BMDCs. Dilc-NLC were co-cultured 
with BMDCs (5 x10
5
 cells) at 1 
µg/ml for 0, 10, 30, or 60 minutes, 
following with surface staining of 
dendritic cell markers CD11c-
BV421. The outline of dendritic 
cells is represented by CD11c 
marker (cyan) in all images and NLC 
particles are represented by Dilc 
dye (red). 
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morphologically different DCs and opportunities to encounter various other cell types, we then 
studied the NLC uptake ex vivo, trying to identify their interaction with different cell populations 
within the lymphatics. Spleen of a NOD mouse was used as it’s an important lymphoid organ, 
and spelenocytes were generated and incubated with Dilc-NLC for different amount of time. 
Different cell populations within the spleen were identified, including T cells, B cell, 
conventional dendritic cells (cDCs), monocyte derived dendrtic cells (moDCs), monocytes, and 
macrophages (Figure 5a), and all these cell populations are able to take up NLC particles 
(Figure 5b). The uptake of NLC particles by different cell populations  
within the spleen confirmed the trend we observed in the previous in vitro study: an initial quick 
uptake of the particle followed by gradual and continuous uptake. Although obtaining similar 
trend, each cell population exhibited different uptaking profile, implying that the particles are 
taken up in an active manner. 
 
NLC Biodistribution and Kinetics. Because of complex in vivo interactions between particles 
and internal circulations and tissues, especially with the fact that different administration routes 
will possibily result in differnet pathways of particle absorption, biodistribution and kinetics of 
NLC via different administration routes were then studied to better locate particles within the 
body and identify the optimal time to observe peak uptake. Lipid nanoparticels were often 
reported to be able to accumulate in lymphatics, thus we started by selecting multiple lymphatic 
tissues that are involved in the development of T1D to study if our NLC particles also behave in 
this unique way, and at which time point after administration will the peak uptake occur. To 
study the impact of differential administration route have on biodistribution and 
pharmacokinetics in vivo, lymphatic tissues including spleen, pancreatic lymph nodes (pLNs), 
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Initially, Dilc-NLC (1 mg) were administrated intravenously (I.V.), intraperitonially (I.P.), 
subcutaneously (SC), or via oral gavage, and aforementioned lymphatic tissues were extracted 24 
hours after Dilc-NLC administration. Mild signals were only observed in spleens (both control 
and experimental groups) from all routes at this time point, yet their intensity has no big 
differences with control tissues, and no other tissue from all routes tested showed any signal 
(Figure 6b).  
Although particles can be taken up within 10 minutes according to our in vitro data, 
twenty-four-hour checkpoint was originally chosen thinking that much longer time is needed 
with longer “traveling” and much more barriers to overcome before encountering APCs in vivo. 
However, the particles might be absorbed and eliminated in a much faster manner than expected, 
and higher dosage of Dilc-NLC might be required to receive stronger signal for any differences 
to be observed. Therefore, we further reduced the time before tissue extraction and increased the 
Dilc-NLC dosage. The biodistribution and kinetics of NLCs via oral gavage was first studied as 
it is the most appealing route and is also our ultimate goal for delivery. The lymphoid tissues 
were extracted from NOD mice 6 hours after administrating Dilc-NLC (5 mg or 15 mg) via 
gavage and examined through IVIS. Stronger signal was observed in spleen, pLN, and partially 
in mLNs of the administrated animals but not in control ones (Figure 7a). However, despite that 
the intensity of signal was positively correlate to dosage, there were no major differences 
between different tissues in term of average radiant efficiency. Thus, observation time was 
further reduced to 2 and 4 hours with the more optimal Dilc-NLC dosage (15 mg) applied. We 
were able to find and extract the other pLN (right) from treated animals this time, and observed 
NLC accumulation in spleen, one of the pLN (left, same as previous), and most of mLNs, but not 
in iLNs. Much stronger signal was detected in these tissues, and the strongest appeared at 2 hours 
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identified that the peak uptake occurred between 1 to 2 hours after administration (Data not 
shown). Based on these results, we confirmed that when administrated orally, our formulation of 
NLC has the unique ability to cross biological barriers and accumulate in the lymphatics, 
reaching selected tissues: spleen, pLN, mLNs, but no iLNs.  
The biodistribution and pharmacokinetics of NLC via I.V. route were then studied using the 
same IVIS based approach. Considering this route would deliver particles directly into blood 
stream and circulate around the whole body, which bypasses several physiological barriers, 
checking timepoint after administration was further reduced as well as the dosage applied. 
Dosage testing were performed first since large amount of lipid injected into circulation may 
cause severe health problems (i.e. cerebral thrombosis and pulmonary embolism) and eventually 
lead to animal death, and 10 mg Dilc-NLC was tested to be able to present strong signal with 
clear differences between tissues while keeping animals alive till euthanasia (around 2 hours). 
Dilc-NLC was injected intravenously, and same set of lymphoid tissues were extracted 0.5, 1, or 
2 hours after administration. IVIS was used to detect particle distribution, and NLC was found 
accumulating in all tissues extracted from the Dilc-NLC injected animals, including the other 
pancreatic lymph node (pLNrigh) and both inguinal lymph nodes, at all time points (Figure 8a). 
The signal in tissues of treated animals were much intense comparing to untreated control, and 
the strongest signal was observed in spleen, which was much than two folds stronger than that in 
pLN (the one placed on the left) (Figure 8b). Comparing to the oral gavage group, more 
particles (reflected by signal intensity) were able to reach and accumulate to lymphoid sites, and 
the peak uptake was even earlier around 30 mins to 1 hour (Figure 8b). These results indicated 
that the biodistribution of NLC changed depending on the administration route chosen, with a 
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related alteration of the peak uptake time as well. The impact that intraperitoneal and 



















































Figure 7. The impact of oral gavage administration route on NLC biodistribution and kinetics. Dilc-NLC 
was administrated into NOD mice via oral gavage and lymphoid tissues including spleen, pLN(s), mLNs, 
and iLNs were extracted at different timepoints (untreated at left; Dil-NLC administrated at right). The 
distribution and uptake of NLCs were determined by fluorescent intensity by IVIS. The color scale is set 
from 2.2e7 to 6.0e7, and the intensity of fluorescent signal from each tissue is shown on the bar graph. 
a. Dilc-NLC at 5 or 15 mg were given to NOD animals and lymphatic tissues were extracted 6 hours after 
administration. b. Dilc-NLC at 15 mg were given to NOD animals and lymphatic tissues (also including 



















































In Vivo NLC Uptake. Our previous studies have demonstrated that NLC particles are taken up 
(in vitro) by different subsets of APCs and other cell populations.  Therefore, it is very important 
to study whether NLCs can be taken up by different cell populations in vivo as multiple 
biological barriers exist and need to be overcome before encountering lymphocytes within 
lymphoid tissues. The biodistribution studies have shown that NLCs can successfully reach  
and accumulate into lymphoid sites after being delivered intravenously or via oral gavage. We 
then studied the uptake profile within those tissues to identify which specific cell populations 
were taking up the particle. The highest uptake of NLCs happens 1 to 2 hours after oral gavage, 
thus the lymphoid tissues including spleen, pLNs, mLNs, and iLNs from Dilc-NLC treated 
animals were extracted 1.5 hours after oral administration. Tissues were digested to separately 
generate splenocytes and lymphocytes, and the uptake of NLC was determined by assessing the 















































Figure 8. The impact of I.V. route on NLC biodistribution 
and kinetics. Dilc-NLC was administrated intravenously at 
10 mg to NOD animals and tissues including spleen, pLNs, 
mLNs, and iLNs were extracted at 0.5, 1, or 2 hours after 
administration (Tissues from untreated animals on the 
left and treated on the right). a. The distribution was 
detected based on the fluorescent intensity of particles 
via IVIS. Color scale was set from 3.5e7 to 5.5e8 in all 
images. b. The accumulation of NLCs at different time 
was more quantitatively reflected based on average 
radiant efficiency on the bar graph. 
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nodes showed fluorescent intensity very close to that of untreated control animals at all 
timepoints and dosage checked (Figure 7), they were used as control tissue in this experiment. 
Although the difference in signal intensity between control and the rest lymphoid tissues was 
clear on IVIS, no significant differences on Dilc intensity were observed among different cell 
populations within spleen, pLNs, or mLNs (Figure 9a), and this result was consistent with 2 
more repeats. Thus, although tissue level NLC uptake can be observed via IVIS, cellular uptake 
of particles cannot be detected via flow cytometry. This might due to limited Dilc intensity 
within each cell. With much stronger signal intensity detected at each lymphatic tissue on IVIS, 
cellular uptake of NLC via I.V. were then studied hoping this time fluorescent would exceed the 
detection threshold of flow cytometer. Spleen of untreated and 10 mg Dilc-NLC treated animal 
were extracted 30 minutes (as previously demonstrated to be within the highest uptake range) 
after intravenous administration, and only spleen was extracted here since not enough cells were 
obtained from other lymphatic tissues after processing. Cellular level uptake of NLC was clearly 
detected, with major peak shift observed compared to control, in all cell populations identified (B 
cells, T cells, cDCs, moDCs, macrophages, and monocytes) within the spleen (Figure 9b). 
Therefore, our formulation of NLCs can also be taken up by different populations of splenic cells 
in vivo, however, the cellular uptake can only be detected by flow cytometer when administrate 




 NLC Mediated Delivery of Tofacitinib 
With all the NLC characterization on uptake and biodistribution, this formulation of particle 
seems to be promising on delivering the cargo of our interest, tofacitinib (Tofa), as it tends to 
accumulate at lymphatic tissues and can be taken up by multiple cell populations as well. Thus, 
we tested whether Tofa encapsulated NLC particles (Tofa-NLC) were capable of delivering 
bioactive Tofa to our cell populations of interest, particularly DCs. Inspired by previous 
demonstrations of our group, in which exposure of DCs to soluble Tofa can influence the 
upregulation of the maturation markers induced by the maturation stimuli LPS, we hereby tested 
the delivering capacity of Tofa-NLC by measuring their ability to inhibit the maturation of DCs 
in response to LPS. Bone marrow derived dendritic cells (BMDCs) were exposed to Tofa-NLC 
or NLC particle itself (Ctrl.NLC) followed by stimulation with LPS, and their maturation level 
was measured by analyzing the expression of cell surface maturation markers CD40, CD80, and 
CD86 via flow cytometry. Dendritic cells with no exposure to particles showed upregulation in 
all markers after stimulation, and those DCs exposed to Ctrl. NLC showed similar maturation 
DC only DC + LPS NLC + LPS Tofa-NLC + LPS 
Figure 10. NLC mediated delivery of Tofacitinib. Bone marrow derived dendritic cells (BMDCs) 
were cultured and exposed to NLC itself (Ctrl. NLC) or NLC loaded with Tofacitinib (Tofa-NLC) for 
6 hours (both particles at a final concentration of 30 µg/ml), followed by LPS stimulation at 
200ng/ml per condition overnight. Cells were collected and stained with dendritic cell marker 
CD11c and maturation markers CD40, CD80, and CD86, DC maturation level were then assessed 
via flow cytometry 
 35 
level in term of the expression of maturation markers (Figure 10). The upregulation of 
maturation markers was prevented after exposing to Tofa-NLC, and the maturation was reduced 
to a level close to that measured in DCs without any stimulation (Figure 10). This data clearly 
shows that our formulation of NLC is able to deliver bioactive anti-inflammatory agent 
Tofacitinib to DCs, which lead to the inhibition of DC maturation.  
       
 The Impact of Enhanced Costimulation Blockade (Tofa-NLC + CTLA4-Ig) on T1D  
The most frequent animal model used in researching type 1 diabetes is the non-obese diabetic 
(NOD) mice, animals that spontaneously develop the disease similarly to humans. In NOD mice, 
insulitis (infiltration of lymphocytes into pancreatic islets) starts very early at 3-4 weeks of age 
followed by overt hyperglycemia beginning at age 10-12 weeks, in which 70-75% of functional 
beta-cells in pancreatic islets have been destroyed. Differences in development of diabetes 
between male and female NODs are observed, and under specific pathogen-free (SPF) 
conditions, females develop diabetes much faster than males (around 90% of females are diabetic 
by 40 weeks, while males only around 30%) [11, 67]. NOD mice were used in studying the 
impact of our ECoB strategy on T1D, and considering that sex is a variable in the development 
of the disease, only females were used in these experiments. Treatments were initiated at two 
stages, either early at 3 weeks old or later at 10 weeks old, since insulitis starts way early than 
diabetes can be detected. Diabetes was monitored by measuring blood glucose level weekly since 
week 10 of age, and a NOD is determined to be diabetic when its blood glucose exceeds 250 
mg/dL for two consecutive days.  
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The Impact of Tofa-NLC on T1D Development. Before studying the ECoB strategy, we first 
studied whether Tofa-NLC itself would has any impact on the development of T1D. Tofa-NLC 
was administrated to NODs via oral gavage at 3 or 10 weeks of age. Both early and late stage 
treatments showed therapeutic effects in delaying the onset of diabetes comparing to untreated 
control animals, especially long-term (> 23 weeks), and the therapeutic effects exhibited in both 
groups were significantly different (p<0.05) (Figure 11a). The releasing profile of Tofa-NLC 
was only recently determined by our collaborators at APL, which showed that approximately 
90% of the Tofa loaded in the particles is released in the initial 24 hours. With this information, 
we are currently testing the impact of Tofa-NLC to 3- or 10-weeks old NODs when delivered via 
an intense regimen, in which total 5 administrations of Tofa-NLC was given one per day for 5 
days via oral gavage, yet it is still too early to determine whether there are any therapeutic effects 
with this new regimen.  
 
The Impact of CTLA4-Ig and CTLA4-Ig + Tofa-NLC on T1D Development. CTLA4-Ig 
(abatacept) prolongs graft survival in transplantation, as described by various studies, while 
dosage remains critical since it can lead to opposite results. Preliminary data show that only 
CTLA4-Ig treated at later stage (10-week) with a lower dosage (500:250) seem to show some 
positive result, while higher dosage (500:500) at later stage and both dosages at earlier stage give 
negative result in delaying diabetes onset comparing to untreated control NODs (Data not 
shown). Hereby, we treated newly defined high dose (500:250) CTLA4-Ig to 10-week-old 
NODs, and reduced the dosage according to animal weight to low dose (250:125) for 3-week-old 
animals. Neither dosage provided protective effect on diabetes onset, and further tested low dose 
(250:125) CTLA4-Ig applied at later stage did not show protective effect either (Figure 11b). 
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Combined therapy (CTLA4-Ig (500:250) + Tofa-NLC) was also applied to NODs at later stage, 
yet surprisingly it again had negative effect on the onset of diabetes, if not behaving even worse 
comparing to CTLA4-Ig applied by itself at the same stage (Figure 11b). Therefore, these data 
suggest that neither CTLA4-Ig by itself or combined with Tofa-NLC at the dosage we tested will 
provide any therapeutic impact on the development of T1D.  
 
 
Elucidate the Mechanism Behind Therapeutic Effect of Tofa-NLC on T1D. Maturing 
antigen presenting cells has been shown to closely related to inflammatory cytokines release, and 
our previous experiments demonstrated that Tofa-NLC can inhibit the maturation of dendritic 
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CTLA4-Ig (500:250)_10 wks (n=4)
CTLA4-Ig (250:125)_10wks (n=4)
Tofa-NLC + CLTA4-Ig(500:250)_10 wks (n=5)


















Ctrl. (n=26)  10-week (n=11) 3-week (n=7)
a. 
b. 
Figure 11. The impact of ECoB on T1D. 
a. Tofa-NLC were administrated to 3- or 
10- week-old NODs via oral gavage one 
administration per day, every other day 
for 5 administrations. Total of 0.5 mg or 
1 mg equivalent Tofa was delivered to 3- 
or 10- week-old NODs over the 
treatment range, respectively. Blood 
glucose levels were monitored weekly 
since week 10 of age, and diabetes was 
determined when blood glucose exceed 
250 mg/dL for two consecutive days. b. 
CTLA4-Ig alone was adminsitrated to 3- 
or 10- week-old mice via I.P. for 4 total 
administrations at day 0, 2, 4, and 6. 
Either high dose (500: 250) or low dose 
(250: 125) were applied, in which 500 or 
250 µg of CTLA4-Ig was injected at the 
first administration while 250 or 125 µg 
was injected in the following ones, 
respectively. CTLA4-Ig was also used 
together with Tofa-NLC, during which 4 
high dose (500: 250) CTLA4-Ig were 
injected via I.P. at day 0, 2, 4, and 6, 
while total of 1 mg Tofa equivalent Tofa-
NLC was delivered via oral gavage at day 
0, 2, 4, 6, and 8. 
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cells in vitro. Thus, the maturation level of different subsets of APCs within lymphatic tissues 
were tested after treating Tofa-NLC via oral gavage with regular regimen in order to understand 
whether this is the reason of the therapeutic effect observed. Maturation level was assessed in 
multiple tissues (spleen, pLNs, mLNs, and iLNs) by measuring the expression of maturation 
markers (CD40, CD80, and CD86) on different subsets of APCs (Figure 12a), however, no 
reduction in the expression of maturation markers was identified among APC subsets within 
different tissues of Tofa-NLC treated mouse compared to untreated control (Figure 12b).  To 
further confirm this is not due to limited detection by flow machine, as we previously 
experienced in studying the cellular uptake of Dilc-NLC in vivo, we repeat the same experiment 
but administrating Tofa-NLC via I.V. There was again no inhibition on APCs’ maturation level 
between the two groups of animals (Figure 12c), therefore, the positive effect Tofa-NLC 
exhibited on delaying the onset of T1D is not a result of inhibiting APC maturation.  
Other ongoing experiments are focusing on studying the mechanism related to the 
protective effect provided by Tofa-NLC. We are examining lymphocytes infiltration in pancreas 
at different age with or without Tofa-NLC treatment, in which histological sections of pancreas 
are obtained and insulitis is scored in 10- and 12- week-old, Tofa-NLC treated (at early or later 
stage) or untreated NOD animals. Given that Treg is critical in controlling the adaptive immune 
system as well as in preventing autoimmune disease, we are also identifying the proportion of 
Treg population within insulin specific T cells in 10-week-old NOD mice treated with (at early 
or later stage) or without Tofa-NLC. Insulin reactive T cells can now be successfully isolated 
from CD4+ T cell population via InsB specific tetramer staining (Figure 13a), and Treg 
population within insulin reactive T cells can be identified. Treg proportion from 10-week-old 






 Confocal imaging shows NLC can be taken intracellularly, but current investigation does 
not provide information on the intake process, whether through endocytosis, diffusion, or some 
other ways. Neither can it tell whether within cytoplasm, the particle remains intact or are being 
lysed as only the Dilc dye loaded can be overserved through the microscope. Future experiments, 
such as applying confocal time-lapse, are needed in order to better observe and study the intake 
process of this formulation of NLC, and a comparison experiment using Dilc dye alone without 
NLC is necessary to test on particle status within cytoplasm. We also need to keep in mind that 
confocal microscope detects fluorescence based on pixel, which in our case is 200 nm, yet the 
size of our NLC particle is approximately 70 nm. Thus, fluorescence detected and observed on 
those confocal images is probably aggregation of particles rather than individual ones, and the 
size of the fluorescent dot appeared to correlate to the amount of particle aggregated.   
 Our NLCs also have the unique property of accumulating into lymphatic tissues, and it is 
very interesting that signals can only be detected from one of the pancreatic lymph nodes when 
administrated via oral gavage, but from both pLNs when administrated intravenously. 
Administration via oral gavage requires active participation of the intestine, which provides 
absorption and digestion of metabolites, and it has been long recognized that specific lymph 
nodes drain different intestine segments [68].  Although both pLNs are closely located next to 
each other, one of them drains primarily the duodenum, while the other drains the transverse 
colon (Figure 14), and this can probably explain why signal was only observed in one pLN after 
oral delivery of Dilc-NLC. The node that particles mainly accumulated to is likely to be the one 
draining form duodenum as it’s the initial place within intestine encountering NLCs after oral 
delivery. Within the time of observation, probably only limited particles are able to travel to and 
absorbed by the transverse colon, thus resulting in the other pancreatic lymph node lacking 
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detectable accumulation of fluorescence under our IVIS setting. Intravenous administration 
allows particles to bypass intestine absorption and entering directly into circulation system, thus 
leading to observation of NLC accumulation in iLNs and both pLNs. No particles were detected 
in iLNs after oral delivery since those lymph nodes do not drain from intestine.  
Figure 14. Lymph drainage along the length of the mucosa [69]. 
  
While treating Tofa-NLC alone provided promising therapeutic effect on delaying the 
onset of T1D diabetes, treatments with CTLA4-Ig gave negative results opposite to what we 
previously observed in the context of transplantation. The reason for costimulation blockade 
having different and even opposite effect in T1D is complicated, as it correlates to the activity of 
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multiple cell types as well as different pathways. Creating a balance between different cells and 
pathways is the key in developing new treatment, yet this is very difficult to manage and achieve. 
 CTLA4-Ig blocks the CD28 pathway by binding to CD80 and CD86 on APCs, 
preventing the activation of effector T cells (Teff), however, it can also affect other T cell 
subsets. For example, it can also block the generation and proliferation of regulatory T cells 
(Treg), whose development and homeostasis highly depend on CD28 pathway as well [70, 71].  
Moreover, the interaction between CD28 and CD80/CD86 regulates the balance between type 1 
T helper cells (Th1), which produces inflammatory cytokines in response to inflammation, and 
type 2 T helper cells (Th2), which produces cytokines essential for humoral responses and 
modulation of Th1 cell differentiation [72], and it has been shown in several autoimmune disease 
settings that CD4+ T cells differentiating towards Th2 is highly dependent on CD28 signaling, 
and disrupting CD28 pathway can lead to earlier onset and accelerated progressing of 
autoimmune disease [22]. Thus, the blockade of CD28 pathway can initiating more protective or 
more inflammatory responses by regulating cytokine balance, leading to positive or negative 
effects in T1D. Moreover, the existence of memory T cells (Tmem) can make co-stimulatory 
blockade less effective, as their activation threshold are much lower, thus less dependent on 
costimulatory signals and more resistant to costimulation blockade [73, 74]. The balance 
between Teff and Treg within pancreas as well as other secondary lymph nodes is very important 
in determining the ultimate fate of beta cells in the context of T1D, therefore, future experiments 
will investigate the Teff to Treg ratio. 
Moreover, CTLA4-Ig can affect the signaling of other co-stimulatory pathways as well 
by interacting with different counter-receptors. For example, the blockade could interrupt the 
CTLA4 co-inhibitory pathway, which binds to the same ligands CD80/CD86 on APCs and plays 
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negative regulatory role by inhibiting T cell activation, reducing the expression of CD80/CD86, 
and increasing the expression of inhibitory molecule indoleamine 2,3-dioxygenase (IDO) [75, 
76]. CTLA4 pathway is essential for immune homeostasis, and its expression on Treg is critical 
for their function [77, 78]. CD80 is also known to interact with programmed cell death 1 ligand 1 
(PDL1), which provides inhibitory signal towards immune responses [79, 80]. Thus, blockade 
with CTLA4-Ig could affect not only CD28, but also CTLA4 and PD-L1 pathways, disturbing 
their inhibitory regulation on autoimmune responses, and leads to opposite outcomes eventually. 
Maybe future studies utilizing costimulation blockade as well as enhanced costimulation 
blockade strategy should choose blockade that binds to CD28 more specifically, such as anti-
CD28 dAb and scFVs [81], in order to minimize the chance of interacting with other receptors 
and hopefully yield better outcomes.  
The application of costimulation blockade was thought to be able to control graft 
rejection in transplant model by inducing T cell anergy, taking advantage of an acute phase 
during which foreign antigens are massively exposed to recipient upon surgery, leading to TCR 
engagement alone. However, autoimmune disease like T1D is a chronic disease and the 
development of autoreactivity spans much longer time-frame and remains quite elusive. There 
would be no moment of a massive presentation of autoantigens, yet before symptoms can be 
observed, autoantigens already exist. Thus, the negative effect CTLA4-Ig provided in our NOD 
model might also be due to lack of autoantigen-specific targeting, which raises the necessity of 
involving T1D autoantigen(s) (i.e. insulin) along with the enhanced costimulation blockade 
treatment to promote effective tolerance.  Application of autoantigen, insulin-specific B peptide, 
is currently studied by our group in a separate project.  
 47 
With all the characterization and elucidation of NLC particles as well as the NLC 
mediated delivery of enhanced costimulation blockade in T1D, future experiments should focus 
on studying the mechanism behind therapeutic effects from Tofa-NLC, exploring better 
treatment regimen according to any further characterization on NLC profile, and testing 
alternative costimulation/CD28 blockade options to better apply the enhanced costimulation 
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